Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world dupilumab in Chinese children 6 months–5 years with severe atopic dermatitis
ChiCTR2200063385Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Eczema Area and Severity Index (EASI) and Investigator Global Assessment (IGA) 0 or 1. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200063385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063385.